Proceedings from a daylong symposium, recorded in October 2019, Orlando, Florida, featuring key clinical presentations and papers in acute leukemias, breast cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, lung cancer and lymphomas and chronic lymphocytic leukemia. Including perspectives from Drs Jeremy Abramson, Johanna Bendell, Michael J Birrer, Julie R Brahmer, Courtney D DiNardo, J Randolph Hecht, Mark Levis, Ursula Matulonis, Craig Moskowitz, Joel W Neal, Eileen M O’Reilly, Joyce O’Shaughnessy, Mark D Pegram, Daniel P Petrylak, David I Quinn and Mitchell R Smith. (Video Program)
TARGET AUDIENCE
This educational activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals.
OVERVIEW OF ACTIVITY
Clinical controversies and uncertainties persist in the management of all common cancers, and thousands of ongoing research trials worldwide attempt to provide new answers to long-standing questions. As these trials reach maturity, clinical investigators initially present new data in abridged format at large scientific conferences and subsequently in full data sets formally published as part of peer-reviewed journals. Today, numerous annual oncology conferences release new clinical data and hundreds of peer-reviewed publications feature articles related to cancer research, treatment and practical management. The extensive list of available treatment options poses a challenge to the practicing clinician who must maintain knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.
These proceedings from a daylong symposium combine the perspectives of 16 renowned investigators with a review of key recent presentations and publications across acute leukemias, breast cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, lung cancer and lymphomas and chronic lymphocytic leukemia to assist medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals in the formulation of up-to-date clinical management strategies.
LEARNING OBJECTIVES
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue
HOW TO USE THESE CME ACTIVITIES
This CME activity consists of a video component.
CME credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
Jeremy Abramson, MD
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Consulting Agreements: AbbVie Inc, Celgene Corporation, EMD Serono Inc, Genentech, Janssen Biotech Inc, Roche Laboratories Inc; Contracted Research: Celgene Corporation, Seattle Genetics.
Johanna Bendell, MD
Chief Development Officer
Director, Drug Development Unit Nashville
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee
Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, ARMO BioSciences, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Continuum Clinical, Cyteir Therapeutics, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Genentech, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, Merck, Merrimack Pharmaceuticals Inc, Moderna Inc, Molecular Partners, Novartis, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Pfizer Inc, PhoenixBio, Prelude Therapeutics, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics, Taiho Oncology Inc, Tanabe Research Laboratories, TG Therapeutics Inc, Tizona Therapeutics Inc, Tolero Pharmaceuticals, Torque Therapeutics, Translational Drug Development; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics SA, Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, Arcus Biosciences, ARMO BioSciences, Array BioPharma Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, CytomX Therapeutics, Daiichi Sankyo Inc, eFFECTOR Therapeutics Inc, Eisai Inc, EMD Serono Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Forty Seven Inc, Genentech, Gilead Sciences Inc, GlaxoSmithKline, Gossamer Bio, Harpoon Therapeutics, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Jacobio Pharmaceuticals Co Ltd, Kolltan Pharmaceuticals Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, MEI Pharma Inc, Merck, Merrimack Pharmaceuticals Inc, Mersana Therapeutics, Merus BV, Nektar, Novartis, Novocure, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pieris Pharmaceuticals Inc, Prelude Therapeutics, Rgenix, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics, Shattuck Labs, Sierra Oncology, SynDevRx Inc, Taiho Oncology Inc, Takeda Oncology, Tarveda Therapeutics, Tempest Therapeutics Inc, TG Therapeutics Inc, TRACON Pharmaceuticals Inc, Tyrogenex Inc, Unum Therapeutics, Vyriad; Data and Safety Monitoring Board/Committee: Five Prime Therapeutics Inc.
Michael J Birrer, MD, PhD
Professor of Medicine/Hematology and Oncology
Evalina B Spencer Chair in Oncology
The University of Alabama at Birmingham
Birmingham, Alabama
No relevant conflicts of interest to disclose.
Julie R Brahmer, MD
Director, Thoracic Oncology Program
Director, Johns Hopkins Kimmel Cancer Center at Bayview
Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland
Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, Lilly, Merck, Roche Laboratories Inc, Syndax Pharmaceuticals Inc; Contracted Research: Bristol-Myers Squibb Company; Data and Safety Monitoring Board/Committee: GlaxoSmithKline.
Courtney D DiNardo, MD, MSCE
Associate Professor, Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Advisory Committee: Jazz Pharmaceuticals Inc; Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Celgene Corporation, Daiichi Sankyo Inc, Notable.
J Randolph Hecht, MD
Professor of Clinical Medicine
Director, UCLA GI Oncology Program
Carol and Saul Rosenzweig Chair in Cancer Therapies Development
Santa Monica, California
Advisory Committee: Gritstone Oncology, Merck; Consulting Agreement: Amgen Inc; Contracted Research: AbbVie Inc, Advaxis Inc, Astellas, Halozyme Inc, Merck, Novartis.
Mark Levis, MD, PhD
Director, Adult Leukemia Program
Co-Division Director, Hematologic Malignancies
Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland
Advisory Committee: Agios Pharmaceuticals Inc, Amgen Inc, Astellas, Daiichi Sankyo Inc, FUJIFILM Pharmaceuticals USA Inc, Menarini Group, Novartis; Contracted Research: Astellas, FUJIFILM Pharmaceuticals USA Inc, Novartis; Data and Safety Monitoring Board/Committee: Astex Pharmaceuticals.
Ursula Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Advisory Committee and Consulting Agreement: Novartis.
Craig Moskowitz, MD
Physician in Chief, Oncology Service Line
Sylvester Comprehensive Cancer Center
Professor of Medicine, Miller School of Medicine
University of Miami Health System
Don Soffer Clinical Research Center
Miami, Florida
Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck, Seattle Genetics, Takeda Oncology; Contracted Research: ADC Therapeutics SA, AstraZeneca Pharmaceuticals LP, Merck, Seattle Genetics.
Joel W Neal, MD, PhD
Assistant Professor of Medicine
Division of Oncology
Stanford Cancer Institute
Stanford University
Stanford, California
Advisory Committee: AstraZeneca Pharmaceuticals LP, Exelixis Inc, Genentech, Jounce Therapeutics Inc, Lilly, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Adaptimmune, Boehringer Ingelheim Pharmaceuticals Inc, Exelixis Inc, Genentech, GlaxoSmithKline, Merck, Nektar, Novartis, Roche Laboratories Inc, Takeda Oncology.
Eileen M O’Reilly, MD
Winthrop Rockefeller Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary/Neuroendocrine Cancers
Gastrointestinal Oncology Service
Associate Director
David M Rubenstein Center for Pancreatic Cancer
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York
Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, CytomX Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, Halozyme Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Merck, Pfizer Inc, Sanofi Genzyme; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Halozyme Inc, Incyte Corporation, Lilly, Novartis.
Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, Texas
Advisory Committee and Consulting Agreements: AbbVie Inc, Agendia Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Genentech, Genomic Health Inc, GRAIL, Halozyme Inc, Heron Therapeutics, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Jounce Therapeutics, Lilly, Merck, Myriad Genetic Laboratories Inc, Novartis, Odonate Therapeutics, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Seattle Genetics, Syndax Pharmaceuticals Inc.
Mark D Pegram, MD
Susy Yuan-Huey Hung Professor of Medicine
Director of the Breast Oncology Program
Associate Dean, Clinical Research Quality
Associate Director for Clinical Research
Stanford Cancer Institute
Stanford University School of Medicine
Stanford, California
Advisory Committee and Consulting Agreements: Genentech, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Samsung Bioepis.
Daniel P Petrylak, MD
Professor of Internal Medicine (Medical Oncology) and Urology
Yale University
New Haven, Connecticut
Consulting Agreements: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Clovis Oncology, Exelixis Inc, Incyte Corporation, Janssen Biotech Inc, Lilly, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seattle Genetics, UroGen Pharma; Contracted Research: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Clovis Oncology, Endocyte Inc, Genentech, Innocrin Pharmaceuticals Inc, Lilly, Merck, Novartis, Pfizer Inc, Progenics Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics; Ownership Interest: Bellicum Pharmaceuticals Inc, Tyme Inc.
David I Quinn, MBBS, PhD
Medical Director, Norris Cancer Hospital and Clinics
Head, GU Cancer Section
Division of Cancer Medicine and Blood Diseases
USC Norris Comprehensive Cancer Center
Los Angeles, California
Advisory Committee and Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Dendreon Pharmaceuticals Inc, Exelixis Inc, Genentech, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, Merck, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seattle Genetics; Data and Safety Monitoring Board/Committee: Children’s Hospital Los Angeles, Eisai Inc, US Biotest Inc.
Mitchell R Smith, MD, PhD
Professor of Medicine
Associate Center Director for Clinical Investigations
Director, Division of Hematology and Oncology
GW Cancer Center
Washington, DC
Data and Safety Monitoring Board/Committee: Eastern Cooperative Oncology Group; Speakers Bureau: AstraZeneca Pharmaceuticals LP, EUSA Pharma.
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies, Amgen Inc, Array BioPharma Inc, Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc and Tolero Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, Genentech, Genomic Health Inc, Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Sanofi Genzyme, Seattle Genetics, Taiho Oncology Inc, Takeda Oncology, and Tesaro, A GSK Company.
Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Release date: January 2020
Expiration date: January 2021
(WIFI is recommended for best performance):